Trial Profile
Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms ROTOR
- 17 Apr 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2022 Planned End Date changed from 1 Dec 2022 to 3 Feb 2023.
- 15 Sep 2021 Status changed from recruiting to active, no longer recruiting.